MajesTEC-9: A randomized phase 3 study of teclistamab versus pomalidomide, bortezomib, and dexamethasone or carfilzomib and dexamethasone in patients with relapsed/refractory multiple myeloma.

被引：0
|
作者：
Touzeau, Cyrille
Hungria, Vania T. M.
Bhutani, Divaya
Landgren, Ola
Vieyra, Diego
Guo, Yue
Verona, Raluca
Miao, Xin
Qi, Mia
Watkins, Latisha
Shah, Priya
Chastain, Katherine
Qi, Ming
Quach, Hang
机构：
[1] Ctr Hosp Univ Nantes, Nantes, France
[2] Clin Sao Germano, Sao Paulo, Brazil
[3] Columbia Univ, Med Ctr, New York, NY USA
[4] Univ Miami, Sylvester Comprehens Canc Ctr, Miami, FL USA
[5] Janssen Res & Dev, Spring House, PA USA
[6] Janssen Res & Dev, Raritan, NJ USA
[7] Janssen Res & Dev, High Wycombe, Bucks, England
[8] Univ Melbourne, St Vincents Hosp, Melbourne, Vic, Australia
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2023年 / 41卷 / 16期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
TPS8067
引用
收藏
页数：1
相关论文
共 50 条
  • [1] MajesTEC-3: Randomized, phase 3 study of teclistamab plus daratumumab versus investigator's choice of daratumumab, pomalidomide, and dexamethasone or daratumumab, bortezomib, and dexamethasone in patients with relapsed/refractory multiple myeloma.
    Mateos, Maria-Victoria
    Bahlis, Nizar J.
    Costa, Luciano J.
    Perrot, Aurore
    Pei, Lixia
    Rubin, Maria L.
    Lantz, Kristen
    Sun, Weili
    Jaffe, Mindy
    Kobos, Rachel
    Nooka, Ajay K.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
  • [2] A phase II study of daratumumab with weekly carfilzomib, pomalidomide, and dexamethasone in relapsed and refractory multiple myeloma.
    Yee, Andrew J.
    Nadeem, Omar
    Rosenblatt, Jacalyn
    Bianchi, Giada
    O'Donnell, Elizabeth
    Branagan, Andrew R.
    Harrington, Cynthia C.
    Agyemang, Emerentia A.
    Gammon, Marilyn T.
    Lively, Kathleen J.
    Packer, Lisette A.
    Bernstein, Zachary S.
    Lyons, Rebecca T.
    Riadi, Manal
    Rowell, Sean M.
    Mcvey, Cailin
    Goguen, Amy C.
    Horick, Nora K.
    Richardson, Paul G.
    Raje, Noopur S.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
  • [3] A phase II study of elotuzumab in combination with pomalidomide, bortezomib, and dexamethasone in relapsed and refractory multiple myeloma.
    Yee, Andrew Jenho
    Laubach, Jacob
    Campagnaro, Erica Leigh
    Lipe, Brea
    Nadeem, Omar
    Cole, Craig
    O'Donnell, Elizabeth
    Schlossman, Robert L.
    Bianchi, Giada
    Branagan, Andrew Robert
    Shapiro, Samantha J.
    Harrington, Cynthia C.
    Burke, Jill N.
    Gammon, Marilyn T.
    Lively, Kathleen J.
    Thorburn, Cassandra Ann
    Mann, Mason L.
    Lohr, Jens Guenter
    Richardson, Paul G.
    Raje, Noopur S.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
  • [4] OVERALL SURVIVAL OF PATIENTS WITH RELAPSED OR REFRACTORY MULTIPLE MYELOMA TREATED WITH CARFILZOMIB AND DEXAMETHASONE VERSUS BORTEZOMIB AND DEXAMETHASONE IN THE RANDOMIZED PHASE 3 ENDEAVOR TRIAL
    Dimopoulos, M.
    Goldschmidt, H.
    Niesvizky, R.
    Joshua, D.
    Chng, W. -J
    Oriol, A.
    Orlowski, R.
    Feng, S.
    Kimball, A.
    Moreau, P.
    [J]. HAEMATOLOGICA, 2017, 102 : 168 - 168
  • [5] A randomized phase 2 study of pomalidomide/dexamethasone with or without elotuzumab in patients with relapsed/refractory multiple myeloma.
    San Miguel, Jesus
    Raab, Marc S.
    Goldschmidt, Hartmut
    Lonial, Sagar
    Richardson, Paul G.
    Shelat, Suresh
    Bleickardt, Eric W.
    Palumbo, Antonio
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
  • [6] OCEAN: A Phase 3, Randomized, Global Study of Melflufen and Dexamethasone Versus Pomalidomide and Dexamethasone in Patients With Relapsed/Refractory Multiple Myeloma Refractory to Lenalidomide
    Sonneveld, Pieter
    Schjesvold, Fredrik
    Robak, Pawel
    Rossjey, Viktor
    Pour, Ludk
    Minarik, Jiri
    Delimpasi, Sosana
    Legic, Wojciech
    Salogub, Galina
    Harmenberg, Johan
    Byrne, Catriona
    Nordstrom, Eva
    Richardson, Paul G.
    [J]. AMERICAN JOURNAL OF HEMATOLOGY, 2019, 94 : S25 - S25
  • [7] Phase 2 study of venetoclax plus carfilzomib and dexamethasone in patients with relapsed/refractory multiple myeloma.
    Costa, Luciano J.
    Stadtmauer, Edward Allen
    Morgan, Gareth John
    Monohan, Gregory P.
    Kovacsovics, Tibor
    Burwick, Nicholas
    Jakubowiak, Andrzej J.
    Mobasher, Mehrdad
    Freise, Kevin
    Ross, Jeremy A.
    Pesko, John Carl
    Munasinghe, Wijith
    Cordero, Jaclyn
    Morris, Lura
    Maciag, Paulo Cesar
    Bueno, Orlando
    Kumar, Shaji
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
  • [8] Carfilzomib–dexamethasone vs bortezomib–dexamethasone in relapsed or refractory multiple myeloma by cytogenetic risk in the phase 3 study ENDEAVOR
    W-J Chng
    H Goldschmidt
    M A Dimopoulos
    P Moreau
    D Joshua
    A Palumbo
    T Facon
    H Ludwig
    L Pour
    R Niesvizky
    A Oriol
    L Rosiñol
    A Suvorov
    G Gaidano
    T Pika
    K Weisel
    V Goranova-Marinova
    H H Gillenwater
    N Mohamed
    S Feng
    S Aggarwal
    R Hájek
    [J]. Leukemia, 2017, 31 : 1368 - 1374
  • [9] Carfilzomib and dexamethasone versus bortezomib and dexamethasone for patients with relapsed or refractory multiple myeloma (ENDEAVOR): a randomised, phase 3, open-label, multicentre study
    Dimopoulos, Meletios A.
    Moreau, Philippe
    Palumbo, Antonio
    Joshua, Douglas
    Pour, Ludek
    Hajek, Roman
    Facon, Thierry
    Ludwig, Heinz
    Oriol, Albert
    Goldschmidt, Hartmut
    Rosinol, Laura
    Straub, Jan
    Suvorov, Aleksandr
    Araujo, Carla
    Rimashevskaya, Elena
    Pika, Tomas
    Gaidano, Gianluca
    Weisel, Katja
    Goranova-Marinova, Vesselina
    Schwarer, Anthony
    Minuk, Leonard
    Masszi, Tamas
    Karamanesht, Ievgenii
    Offidani, Massimo
    Hungria, Vania
    Spencer, Andrew
    Orlowski, Robert Z.
    Gillenwater, Heidi H.
    Mohamed, Nehal
    Feng, Shibao
    Chng, Wee-Joo
    [J]. LANCET ONCOLOGY, 2016, 17 (01): : 27 - 38
  • [10] phase II study of daratumumab with weekly carfilzomib, pomalidomide, and dexamethasone in relapsed and refractory multiple myeloma
    Yee, Andrew
    Nadeem, Omar
    Rosenblatt, Jacalyn
    Sperling, Adam
    Bianchi, Giada
    Munshi, Nikhil
    O'Donnell, Elizabeth
    Branagan, Andrew
    Avigan, David
    Liegel, Jessica
    Harrington, Cynthia
    Agyemang, Emerentia
    Lively, Kathleen
    Packer, Lisette
    Han, Samuel
    Minsky, Cole
    Riadi, Manal
    Mcvey, Cailin
    Donnelly, Kaleigh
    Smith, Caitlin
    Katzeff, Mackenna
    Goguen, Amy
    Horick, Nora
    Richardson, Paul
    Raje, Noopur
    [J]. CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2023, 23 : S220 - S221
12345